Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, Bellesoeur A, Servois V, Hequet D, Laas E, Kirova Y, Cabel L, Pierga JY; Institut Curie Breast Cancer and COVID Group; Bozec L, Paoletti X, Cottu P, Bidard FC. Vuagnat P, et al. Among authors: laas e. Breast Cancer Res. 2020 May 28;22(1):55. doi: 10.1186/s13058-020-01293-8. Breast Cancer Res. 2020. PMID: 32460829 Free PMC article.
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F. Hamy AS, et al. Among authors: laas e. Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309. Ann Oncol. 2017. PMID: 28911063 Free article.
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F. Hamy AS, et al. Among authors: laas e. Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27. Breast Cancer Res Treat. 2018. PMID: 29374852
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F. Hamy AS, et al. Among authors: laas e. J Clin Oncol. 2019 Mar 10;37(8):624-635. doi: 10.1200/JCO.18.00636. Epub 2019 Jan 31. J Clin Oncol. 2019. PMID: 30702971 Free PMC article.
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F. Hamy AS, et al. Among authors: laas e. Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12. Clin Cancer Res. 2019. PMID: 31515462
Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer.
Hamy AS, Derosa L, Valdelièvre C, Yonekura S, Opolon P, Priour M, Guerin J, Pierga JY, Asselain B, De Croze D, Pinheiro A, Lae M, Talagrand LS, Laas E, Darrigues L, Grandal B, Marangoni E, Montaudon E, Kroemer G, Zitvogel L, Reyal F. Hamy AS, et al. Among authors: laas e. Oncoimmunology. 2019 Nov 14;9(1):1677427. doi: 10.1080/2162402X.2019.1677427. eCollection 2020. Oncoimmunology. 2019. PMID: 32002287 Free PMC article.
114 results